NCT03118180 - CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 5, 2017

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2020

Conditions

Lymphoma

Interventions

BIOLOGICAL

CD19 targeted chimeric antigen receptor T cells

CD19 targeted chimeric antigen receptor T cells for refractory and relapsed B cell lymphoma

Trial Locations (1)

RECRUITING

the First Affiliated Hospital,School of Medicine, Zhejiang University, Hangzhou